×

All New Biotech Specs: Part 4

Biotech offers some of the best speculation in the market right now, which is why Cramer has dedicated an entire week to the subject. Between companies releasing data on cutting-edge drugs, which can definitely catalyze a stock, and big-pharma names searching for acquisitions, there’s much money to be made in this sector.

Cramer already covered rare diseases, hepatitis C and cancer diagnostics, and on Thursday he turned his attention to diabetes. Sanofi-Aventis is the best big-pharma play on this, but one disease is rarely enough to move the needle at a company of this size. The better trade then is to go with a purer play—or two.

So who are these potentially winning companies? Watch the video to see Cramer’s full report.

Call Cramer: 1-800-743-CNBC

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the Mad Money website? madcap@cnbc.com